CEO: Corey Fishman

Advent Contact: Shahzad Malik

Novel oral carbapenem for the treatment of multi-drug resistant pathogens

Iterum is a clinical stage company developing a novel oral carbapenem, sulopenem, for the treatment of serious hospital and community-acquired infections including complicated urinary tract infections, uncomplicated urinary tract infections and complicated intra abdominal infections .


Advent invested in the Series B round in 2017